Covered recipient · General Payments record
KEVIN PEREZ
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$4,230.35
- Reported across 186 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $612.99 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $289.47 | 5 |
| Gilead Sciences, Inc. | $163.97 | 3 |
| Exact Sciences Corporation | $60.29 | 3 |
| Celgene Corporation | $20.42 | 1 |
| Exelixis Inc. | $18.08 | 1 |
| JAZZ PHARMACEUTICALS INC. | $16.89 | 1 |
| Merck Sharp & Dohme Corporation | $15.93 | 1 |
| GlaxoSmithKline, LLC. | $13.97 | 1 |
| SOBI, INC | $13.97 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $135.14 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117351261 | CMS |
| Amgen Inc. | $135.14 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117351265 | CMS |
| Amgen Inc. | $4.64 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117351263 | CMS |
| Amgen Inc. | $10.56 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117653334 | CMS |
| Amgen Inc. | $3.99 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117653336 | CMS |
| Celgene Corporation | $20.42 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101077684 | CMS |
| Exact Sciences Corporation | $20.51 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114831468 | CMS |
| Exact Sciences Corporation | $19.20 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114831473 | CMS |
| Exact Sciences Corporation | $20.58 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114831479 | CMS |
| Exelixis Inc. | $18.08 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138571873 | CMS |
| Gilead Sciences, Inc. | $23.82 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133733499 | CMS |
| Gilead Sciences, Inc. | $116.59 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133733501 | CMS |
| Gilead Sciences, Inc. | $23.56 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133733503 | CMS |
| GlaxoSmithKline, LLC. | $13.97 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116547717 | CMS |
| JAZZ PHARMACEUTICALS INC. | $16.89 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151316629 | CMS |
| Merck Sharp & Dohme LLC | $15.93 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141969109 | CMS |
| SOBI, INC | $13.97 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141416014 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.